Core Viewpoint - Haohai Biological Technology (06826) plans to acquire approximately 19.8% and 2.4554% equity stakes in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for approximately 38.35 million yuan and 4.756 million yuan respectively, aiming to enter the high-value medical device market of biological amniotic membranes and expand its business in orthopedics and ophthalmology [1] Group 1 - The target company's products are primarily used in orthopedics and ophthalmology for tendon injury repair, ocular surface burns, wound and lesion repair, and support after lacrimal duct obstruction [1] - By investing in the target company and obtaining distribution rights for its products in China, the company will enhance its existing product portfolio and expand its business layout in the orthopedic and ophthalmic fields [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the company with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive subsequent product innovation and technological upgrades [1]
昊海生物科技(06826)拟收购江西瑞济生物工程技术股份有限公司约19.8%股权